NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing NV-387's proposed mechanism targeting viral cell attachment pathways common across filoviruses. This positions NV-387 as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as the World Health Organization reports new cases of Ebola virus disease in the region, underscoring the need for effective treatments. NanoViricides noted that NV-387 is designed to inhibit viral entry by binding to conserved regions on the virus surface, a strategy that could be effective against multiple filovirus strains. The company believes that an oral drug with broad-spectrum activity could be critical for outbreak control, especially in resource-limited settings.
NanoViricides' lead drug candidate, NV-387, is being developed as a treatment for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. In addition, the company has developed NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir within polymeric micelles.
The company's platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific mechanisms for human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses.
As with any drug development, NanoViricides cautioned that there can be no assurance that NV-387 or any of its candidates will demonstrate sufficient effectiveness and safety for human clinical development. The company emphasized the lengthy and capital-intensive nature of pharmaceutical development.
For more information, visit the company's newsroom at https://ibn.fm/NNVC and view the full press release at https://ibn.fm/mm3Z5.
